Successfully treating type 2 diabetes may involve focusing on brain neurons, rather than simply concentrating on obesity or insulin resistance, according to a new study. For several years, researchers ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

UnitedHealth stock is rising after declining for eight consecutive sessions, Applied Materials issues a disappointing revenue ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Novo Nordisk has replaced CEO Lars Fruergaard Jorgensen amid competitive pressures in the obesity drug market. His exit comes ...